COMPASS Pathways (NasdaqGS:CMPS) drew fresh attention after announcing a multi-site randomized controlled trial with the U.S. Department of Veterans Affairs to evaluate its COMP360 psilocybin therapy in veterans with treatment resistant depression and PTSD.
See our latest analysis for COMPASS Pathways.
The VA trial news lands after a sharp run in COMPASS Pathways' share price, with a 30 day share price return of 12.63% and a year to date share price return of 112.37%. The 1 year total shareholder return of 240.10% points to strong longer term momentum relative to recent months.
If this kind of clinical news has your attention, it could be a good time to see what else is moving in healthcare related AI. Check out the 41 healthcare AI stocks
After a 1 year total return above 200% and fresh VA trial headlines, some investors will feel pressure to act quickly on COMPASS Pathways. Others may prefer to wait. The numbers can help frame that choice next.
Most Popular Narrative: 43.1% Undervalued
Against the last close at $13.91, the most followed narrative on COMPASS Pathways points to a fair value of $24.47, built on detailed trial, revenue and margin assumptions.
Completion of enrollment in the COMP006 Phase III trial and the plan to use 9 week data from Part A together with 26 week COMP005 data to support a rolling NDA process could shorten the path to potential approval, which would bring revenue forward and may support earlier earnings visibility.
Want to see what sits behind that fair value gap for COMPASS Pathways? The narrative leans on rapid revenue ramp, rising margins and a rich future earnings multiple. Curious how those moving parts line up and what kind of growth curve is baked in.
Result: Fair Value of $24.47 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the COMPASS Pathways story still hinges on successful Phase III outcomes and FDA decisions, as well as managing future financing needs without heavy shareholder dilution.
Find out about the key risks to this COMPASS Pathways narrative.
Another View: What Multiples Say About COMPASS Pathways
The fair value narrative for COMPASS Pathways leans heavily on future cash flows and long term revenue growth. Yet on a simpler yardstick like P/B, the stock looks expensive at 22.8x compared with 9.6x for peers and 2.5x for the broader US Biotechs industry. That kind of gap can either signal a premium story or raise questions about valuation risk.
For a closer look at how this compares to other companies, and what the numbers imply for valuation risk, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With COMPASS Pathways drawing strong reactions on both risks and rewards, this is a moment to look at the data yourself and decide quickly where you stand. To see both sides in one place, review the 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond COMPASS Pathways?
If COMPASS Pathways has sharpened your focus, do not stop here. Fresh ideas can help you stay ready for the next move and avoid regret later.
- Target potential mispricing by scanning companies that screen as 51 high quality undervalued stocks before the wider market catches on.
- Strengthen your downside protection by focusing on businesses in the 79 resilient stocks with low risk scores to help keep volatility from taking over your portfolio.
- Add quality to your watchlist by searching for companies from the solid balance sheet and fundamentals stocks screener (50 results) so your capital works in sturdier businesses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com